Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

Item

http://www.wikidata.org/entity/Q38621699

Q38621699

about

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

Item

http://www.wikidata.org/entity/Q38621699

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Randomized study comparing ful ...... c colorectal cancer: NORDIC 9.

@en

type

Item

label

Randomized study comparing ful ...... c colorectal cancer: NORDIC 9.

@en

prefLabel

Randomized study comparing ful ...... c colorectal cancer: NORDIC 9.

@en

P1476

Randomized study comparing ful ...... ic colorectal cancer: NORDIC 9

@en

P2093

- on behalf of the Academy of Geriatric Cancer Research (AgeCare)

http://www.w3.org/2001/XMLSchema#string

Bengt Glimelius

http://www.w3.org/2001/XMLSchema#string

Halfdan Sorbye

http://www.w3.org/2001/XMLSchema#string

Pia Österlund

http://www.w3.org/2001/XMLSchema#string

Åke Berglund

http://www.w3.org/2001/XMLSchema#string

P2860

Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example

The timed "Up & Go": a test of basic functional mobility for frail elderly persons

New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin.

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.

Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992-2008.

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.

The vulnerable elders-13 survey predicts 5-year functional decline and mortality outcomes in older ambulatory care patients

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.

P2888

s12885-017-3526-8

P304

548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12885-017-3526-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Per Pfeiffer

Camilla Qvortrup

Stine Brændegaard Winther

P577

2017-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091206729

http://www.w3.org/2001/XMLSchema#string

P698

28814275

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5559862

http://www.w3.org/2001/XMLSchema#string

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

about

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P921

P932